Core Insights - InterCure reported preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 compared to the same period in the previous year [1][5][6] - The company achieved positive Adjusted EBITDA for the twelfth consecutive half-year, indicating consistent operational profitability [1][5][6] - Significant revenue generation from the German market began in the second half of 2025, contributing to the company's global expansion strategy [1][6] Financial Performance - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Cash on hand as of December 31, 2025, was NIS 43 million [5] - The company resumed production and sales from the Nir Oz facility after disruptions due to the October 7, 2023 attack [5] Strategic Developments - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - The company entered into a share purchase agreement to acquire Botanico Ltd., expected to enhance access to premium U.S. genetics and cultivation technologies, with anticipated revenues of over NIS 30 million in the second half of 2026 [5][6] - A strategic investment and collaboration agreement with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51% within two years, enhancing research and pharmaceutical capabilities [5][6] Regulatory and Market Positioning - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations and believes it is well-positioned to benefit from evolving market conditions [5][6] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [6][7]

Core Insights - InterCure reports preliminary estimated revenue of NIS 265 million for 2025, marking an 11% increase compared to 2024, with nearly 20% revenue growth in the second half of 2025 [1][5] - The company achieved its twelfth consecutive half-year of positive Adjusted EBITDA, indicating consistent financial performance [1][5] - Significant revenues were generated from the German market during the second half of 2025, highlighting successful market expansion efforts [1][4] Financial Highlights - Estimated annual revenue for 2025 is NIS 265 million, with approximately NIS 135 million generated in the second half [5] - Positive Adjusted EBITDA is expected in both halves of 2025, continuing the trend of financial stability [5] - Cash on hand as of December 31, 2025, is reported at NIS 43 million [5] Strategic Developments - The company resumed production, importation, and sales from the Nir Oz facility after disruptions due to the October 2023 attack [5] - InterCure launched over 70 new GMP SKUs in 2025, establishing category-leading positions in premium medical products [5] - A strategic acquisition of Botanico Ltd. is anticipated to enhance access to premium U.S. genetics and cultivation technologies, with expected revenues of over NIS 30 million in the second half of 2026 [5] - A partnership with Cannasoul R&D Ltd. was established, acquiring a 28% stake with an option to increase to 51%, enhancing research and pharmaceutical capabilities [5] Regulatory and Market Position - The company is closely monitoring regulatory developments in the U.S. regarding cannabis regulations, positioning itself to benefit from evolving market conditions [5] - InterCure's vertically integrated model and international partnerships are expected to drive long-term value for patients and shareholders [4][5]

Canadian Cannabis Companies Are Dominating Global Deals - Moby THE GIST The cannabis industry is emerging from the doldrums with a splashy deal: Canadian firm Organigram (OGI) will pay up to €250 million (about $295 million) for German medical cannabis producer Sanity Group. That breaks down to an up-front consideration of €113.4 million plus a maximum earn-out of up to €113.8 million tied to financial performance. WHAT HAPPENED The deal gives Organigram a footprint in the E.U. as more countries on the ...

Core Viewpoint - Organigram is set to acquire Sanity Group, a leading German cannabis company, to enhance its position in the global cannabis market, particularly in Europe, which is experiencing rapid growth in both medical and recreational cannabis sectors [1][2]. Acquisition Details - The acquisition will involve an upfront payment of €113.4 million, consisting of €80 million in cash and €33.4 million in Organigram shares, with an additional earnout of up to €113.8 million based on Sanity's financial performance [1][3]. - The share price for the upfront consideration is set at C$3.00, representing a 71% premium over the closing price of C$1.75 on February 17, 2026 [1][3]. - The acquisition is expected to close in the second quarter of 2026, subject to regulatory approvals and shareholder consent [3][4]. Financial Performance of Sanity Group - Sanity Group's annual net revenue grew from €9 million in 2023 to €60 million in 2025, with €19 million generated in Q4 2025 alone [1][2]. - The company has improved its gross margin from 15% in 2023 to 47% in 2025, indicating strong operational efficiency [1][2]. - The German medical cannabis market, where Sanity operates, was valued at over €2 billion in 2025 and is projected to exceed €4.5 billion by 2028, with a 50% year-over-year growth rate [1][2]. Strategic Rationale - The acquisition will allow Organigram to leverage Sanity's established presence in Europe, enhancing its ability to sell higher-margin products and capture more value in the cannabis supply chain [1][2]. - Sanity's expertise in navigating European regulatory frameworks will be critical as Organigram expands its footprint in new markets, including the UK and Poland [1][2]. - The combined entity will strengthen Organigram's competitive edge in the world's largest federally legal cannabis markets, positioning it as a leader in both Canada and Germany [2][3]. Funding and Financial Structure - The cash component of the acquisition will be financed through a combination of cash on hand, a new credit facility, and a C$65.2 million equity investment from British American Tobacco (BAT) [1][3]. - Organigram has secured a senior secured credit facility of up to $60 million to support the acquisition and related expenses [3][4]. - The earnout consideration will be contingent on Sanity achieving specific financial performance metrics, ensuring that the acquisition is financially accretive [2][3].

Core Insights - The cannabis industry is undergoing significant transformation with increased regulation and accountability, moving from a lack of oversight to stringent compliance requirements [1] Industry Developments - Legalization and lab testing have become standard practices, reflecting a shift towards transparency and quality assurance in the cannabis market [1] - The demand for compliance documentation has intensified, indicating a more structured approach to cannabis regulation [1] Company Innovations - SMX is introducing a tamper-proof, invisible molecular ID for every product, which aims to eliminate issues related to lost packages, fraud, and uncertainty in the cannabis supply chain [1]

Core Insights - The article highlights Alan Brochstein's extensive experience in the investment industry, particularly his focus on the cannabis sector since 2014 [1] - Brochstein has been instrumental in providing independent consulting services and has developed a subscription service for cannabis stocks [1] - The article emphasizes Brochstein's advocacy for ETFs, showcasing his efforts to educate investors about the ETF landscape and risks associated with them [1] Group 1: Professional Background - Alan Brochstein has over 10 years of experience in the investment banking sector, with a career starting in 1986 after earning a degree in Economics and Mathematical Methods [1] - He founded AB Analytical Services in 2007 to offer consulting to registered investment advisors and has prepared management reviews for firms evaluating management teams [1] - Brochstein has been a significant figure in the cannabis industry since 2014, launching 420 Investor in 2013, which focuses on cannabis stocks [1] Group 2: ETF Focus - Brochstein has been writing extensively about ETFs since 2025, aiming to help investors understand the diverse ETF universe [1] - He maintains a 79-ETF Focus List that includes both popular and lesser-known ETFs that he believes stand out [1] - A model portfolio was created by Brochstein as of year-end 2025 to assist investors in managing their ETF investments [1]

Core Viewpoint - Curaleaf Holdings, Inc. has announced a change in the date of its special meeting to seek shareholder approval for a proposed arrangement involving the continuation of the Company from British Columbia, Canada to Delaware, USA, aiming to enhance shareholder participation and streamline the approval process [1]. Group 1: Meeting Details - The special meeting was initially scheduled for February 23, 2026, but has been postponed to align with the annual general meeting expected in the second quarter of 2026 [1]. - The Company believes that combining the special meeting with the annual general meeting will promote greater shareholder participation and result in a more cost-effective use of resources [1]. Group 2: Company Overview - Curaleaf is a leading international provider of consumer cannabis products, known for its quality, expertise, and reliability [1]. - The Company operates under various brands, including Curaleaf, Select, Grassroots, Find, Anthem, and The Hemp Company, providing industry-leading service and product selection across medical and adult-use markets [1]. - Curaleaf has a strong presence in all stages of the supply chain and a unique distribution network throughout Europe, Canada, and Australasia [1].

Core Viewpoint - Canopy Growth Corporation (NASDAQ:CGC) is undergoing significant financial restructuring to improve its balance sheet and extend debt maturities, while facing challenges in valuation and market conditions [1][3]. Group 1: Financial Adjustments - Alliance Global analyst Aaron Grey has reduced the price target for Canopy Growth Corporation from C$2.50 to C$1.80, maintaining a Neutral rating due to uncertainties regarding veteran reimbursement changes and potential gross margin pressures [1]. - The company has announced a recapitalization plan that includes securing a new US$150 million term loan due in 2031 to refinance existing debt and enhance working capital flexibility [3]. - Canopy Growth has also reached an agreement to exchange a portion of its 2029 convertible debentures for new 2031 debentures, cash, equity, and warrants, which aims to improve capital structure flexibility and provide multi-year liquidity visibility [3]. Group 2: Company Overview - Canopy Growth Corporation, founded in 2013 and headquartered in Smiths Falls, Ontario, is involved in the production and distribution of recreational and medical cannabis products across various markets [4].

Group 1 - Tilray Brands, Inc. (NASDAQ:TLRY) is recognized as one of the best cannabis stocks to invest in currently [1][2] - The company is the largest cannabis firm in Canada by revenue and ranks as the fourth-largest craft brewer in the US [3] - Tilray operates in four segments: cannabis, distribution, beverage, and wellness, focusing on the production, processing, and marketing of cannabis products globally [5] Group 2 - Canaccord analyst Kenric Tyghe initiated coverage on Tilray with a price target of C$13 and a Hold rating, citing legislative obstacles and structural inefficiencies in the Canadian cannabis industry [3] - Roth Capital maintained a Neutral rating on Tilray after its second-quarter results, reducing its price target from $20 to $10, highlighting the importance of US legislation for the company's future [4] - The company faces potential risks related to intoxicating hemp products, which could lead to prohibitions if not addressed by November 13, 2026 [4]

Core Insights - Village Farms International, Inc. (NASDAQ:VFF) is recognized as one of the best cannabis stocks to invest in currently [1][2] Product Development - The company, through its subsidiary Leli Holland, has launched ten new cannabis product lines in the Netherlands, focusing on consumer insights and operational expertise from global legal cannabis markets [3] - The new product portfolio emphasizes competitive distinctiveness, specific consumption occasions, and innovative formats, tailored to the Dutch legacy market [3] Export Growth - Village Farms has been awarded the 2026 BC Export Awards in the Consumer Products category, reflecting its significant growth in export sales, which increased by 758% year over year as of September 30, 2025 [4] - The company's export operations are supported by EU GMP-certified facilities covering 4.8 million square feet, catering to highly regulated global medical markets [4] Operational Segments - Village Farms operates agricultural greenhouse facilities across the United States and Canada, with key segments including Canadian Cannabis, U.S. Cannabis, Produce, Energy, and Leli [5]